Immunic to participate in scientific and investor conferences in february

New york , jan. 25, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in february: february 1-2: 31st pharmacovigilance 2023 . darius-jean namdjou, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking